��ҩ�з�չ��ذ�ը��ʱ��Խ��

2013-1-29

��ҩ��ҵ��λ֪��ʦ��Ŀǰҩ�￪��״̬��ʾ��ҩ�з��Ѿ��֡��ڴӻ�ѧҩƷ��ҩƷ�Ŀ��У��ѧ��Źؼ��Ե��á�

��߶��ҩ��Ч��ʹ��ҩ�з��ҩ��ģʽ�Եø�Ϊ��С��µ�һ����Ʒ��Ϊ��ҩ��ص��ҩ�￪��׷�ϻ��ѧ��Ĳ��༫��ҵǱ��ҩ��ʹ��ǵó��Ľ��ۣ��Ԥ��ڡ�ʮ��Ԫ��ϵġ��ذ�ը��Ʒ��ʱ��Ϊʱ��硣

��Ľ��ֱ�Խ��һ��ʱ�ڶ��ּ��ҩ��з��Ԥ��չ��Թ۲조δ��һ��ҩ�з��Ķ��ơ�

��͸��ҩ���ɼ��

��Ż��߶Ը��ȫ�͸��ҩƷ��ӣ��͸��ҩ��Ŀ��ͷ��δ��ҵǰ��ɹۡ�

��Ȼ��2012��4��ٿ��ŷ�޸��о�Э��(EASL)��47��ʸβ��ϣ��ۺ�ø��Ƽ�(NUC)��ͷ��2012��8�£��ʱ��ʩ��/Inhibitex��˾��NUC��BMS-986094��Ѫ�ܲ��Ӧ��ֹ�о��Idenix��˾��NUCҩ��IDX719Ҳ��ȫ��ⲻ�ò��ٴ��ʳƷҩƷ��(FDA)�ύ��롣��񣬽�ʣ�¼��¿�ѧ��˾��sofosbuvir(GS-7977)��ٴ��׶Ρ��ܹ��׼��EvaluatePharma��ѯ��˾Ԥ��2018��ҩ��۶�ﵽ58��Ԫ��

��ʱ��ʩ��/ǿ��/Medivir��˾��ĵ��ø��Ƽ�simeprevir��Ŀǰ��ڽ��԰�ʱ��ʩ��NS5A��Ƽ�daclatasvir��ɵĸ��ҩ��Ϊ��յ��о��粻��⣬��ҩ��ܻ��2014��С�

��Ŀڷ�NS34A��Ƽ�ABT-450��ļ��Τ��ڢ��ٴ��׶Σ�Ŀ��2015��С�2012��11��ڲ�ʿ��ٿ��β��о�Э��(AASLD)��ϣ��ʾ��ABT-450�ڢ�b��ٴ��еõ��ý��ADIS R&D Insight��˾Ԥ�⣬��2019�꣬ABT-450��ȡ�á��ذ�ը��

��Ͻ��ص��ڷ�NUCs��ڿ��setrobuvir��danoprevir��mericitabine�͸��Ƽ�(Ŀǰ�ѽ��ٴ��׶�)��

��Achillion��ҩ��˾�ĵ��ø��Ƽ�sovaprevirĿǰҲ�ѽ��ٴ��׶Ρ�

����ʪ�ؽ��ҩ�JAK3��Ƽ�ռ��

��Ȼ��JAK3��Ƽ�tofacitinib��һ��İ�ȫ��⣬��ջ��2012��11�»��׼��Decision Resources��˾��ʦ��˶��ά��Ϊ��tofacitinib�ǹ�ȥ10��һ��׼�Ļ��ⲡ�鿹��ʪҩ(DMARDs)��Ԥ�Ƹ�ҩ2018��۶�ﵽ12��Ԫ��ADIS R&D Insight��˾Ԥ��ҩ��2015��ͻ�ﵽ��ذ�ը��λ��

��µİ��ľ��ר��ʱ�仹�磬��ù�˾�Ѿ��ѿ��ڷ�JAK��Ƽ��Ϊ��δ��ʪ�ؽ��ҩ��о��ص㡣2012��2�£��ͨ��ʱGalapagos��˾ǩ��һ���Э�飬��˿ڷ�JAK1��Ƽ�GLPG 0634(Ŀǰ�ѽ��ٴ��׶�)��GLPG 0634�ڶ�ŷ��չ��ٴ��ȡ��˲��Ч��ҵ��Ԥ��GLPG 0634��׼��Ϊ2017��1�¡�

��Incyte��˾��ͬ��baricitinibҲ��һ�ֿڷ�JAK��Ƽ��Ŀǰ�ѽ��ٴ��׶Ρ�

��ڷ�JAK��Ƽ��ʪ�ؽ��ҩ��Ψһѡ��Rigel��ҩ�Ͱ�˹��辶��˿ڷ�Syk��ø��Ƽ�fostamatinib(Ŀǰ�ѽ��ٴ��׶�)��˶��άԤ�⣬fosamatinib��2015��У��2018��۶��ﵽ4.5��Ԫ��

��֢ҩ���ɹ��

��ڰ�֢ҩ��Ǵ�ͳ��쵼�߻��Ǻ��֮�㣬��ȡ�õĳɹ��޲��߲�Ʒ�İ�ȫ�Ժ��Ч�ԡ�

��ڶ��Ժ�ɫ��Zelboraf��BRAF��Ƽ��Ч��Ѹ�٣��õ��Ʒ�Ӧ�ʣ��ֻ�д�Լһ��Ļ��ߴ��BRAFͻ�䡣��Zelboraf/GDC-0973��Ƽ��Ģ��ٴ��飬��Ǵ�Exelixis��˾�ļ�ø��Ƽ��з�ƽ̨��õ�һ��С��MEK��Ƽ��

��ʷ��Ҳ��ڿ��Zelboraf�Ķ��Ժ�ɫ��ҩ��BRAF��Ƽ�dabrafenib��ҩ�뷨��bioMerieux SA��˾�Ĵ��ϲ�Ʒͬʱ��ʷ�˵��Ϳڷ��ҩ��dabrafenib��ʷ��/�ձ��̲ݹ�˾��MEK��Ƽ�trametinib��Ƽ�Ҳ��ڿ��С�dabrafenib��trametinib��Ϊ��һ��ҩ��ֱ��ŷ�޽��Ԥע�ᣬ��ʷ��ڽ��临��Ƽ��Ģ��ٴ��顣��2012��ٴ��ѧ��(ASCO)��Ϲ��ٴ��о��ʾ��dabrafenib��trametinib��BRAFͻ��ɫ��Ч��ڻ��ҩ�

��ʱ��ʩ�󱦵�nivolumab��Ƴ��1(PD-1)�ĵ��¡��壬Ŀǰ�ù�˾��ڶ��ƶ��Ժ�ɫ��(��ձ��о�)��Сϸ��ΰ��Լ��֢��о��

��ٰ��ϵ�T-DM1(��鵥��emtansine)��Ϊ��ٰ��Ķ��ҩ��ѽ��Ԥע�ᡣT-DM1��ϵĺ��͡(��鵥��)ͨ��ImmunoGen��˾�Ŀ��˿��Ѽ�DM1��ӳɵľ��ϸ��õĿ��ҩ�ﹲ��Dako HercepTest��HER2 FISH pharmDx��Լ��ΪT-DM1�Ĵ��Լ��TDM-1��Ϊ��ҩ��׼��Ԥ�ƻ��Ϊ��һ��ҩ��Ӧ֤��͡��ŷ�˵�ר��2014�굽�ڣ��Ҫ��4��ҵ��ڡ��ɭ·͸��Decision Resources��Kantar Health��˾��Ԥ��T-DM1��ﵽ��ذ�ը��

��ǰ��ٰ��Ų��＼��˾Algeta�Ͱݶ��ڿ��-223�Ȼ��ҩ��(ŷ��Ʒ��ΪAlpharadin��Ʒ��ΪXofigo)��Ŀǰ�ѽ��ٴ��׶Ρ��-223�Ȼ��ӵ��һ��ȫ�µ��û��ƣ��˷��ͬλ�أ��Ϊ��ģ��ڹ�ת�ƣ��Ӱ��Ĺ��衣Algeta��˾��ڶԸ�ҩ��ת��Լ��صֿ��ǰ��ٰ��в��ԣ��ݶ��ѿ�ʼ��ô�ŷ�޺��ɫ�жԸ�ҩ��Ӧ֤�о��

��Aragon��ҩ��˾��ڿ��ǰ��ٰ�ҩ��ARN 509Ŀǰ��о��׶Σ��ҩ��ڶ�Zytiga��û��Ӧ��Ļ��ߡ�

��ѪҺ��Ariad��ҩ�ļ��ܰ�ϸ��Ѫ��(ALL)��ϸ��԰�Ѫ��(CML)ҩ��ponatinib��ڵȴ��ŷ��׼��Decision Resources��˾Ԥ��ҩ��2018��ᳬ��8��Ԫ��

��Celgene��˾�Ķ෢�Թ��ҩ��pomalidomide��ŷ�޽��Ԥ��ע�ᣬ��Ĵ��ҩ��ʹ��շѷ��(PDUFA)��Ϊ2013��2�¡�

��Pharmacyclics��˾��ɭ��＼��˾��ibrutinib��һ��ܰ�ϸ��Ѫ��(CLL)��Bruton�Ұ��ἤø(BTK)��Ƽ��Ŀǰ��ڢ��ٴ��׶Ρ��ɭ·͸Ԥ�⣬��ҩ��׼��2017�꽫�ﵽ��ذ�ը��

��֬Ѫ֢ҩ�CETP��Ƽ��

��CETP��Ѫ��е�һ��ǵ��ף��ܹ��ѵ��̴��Ӹ��ܶ�֬��(HDL)ת��Ϊ��ܶ�֬��(LDL)��ܶ�֬�� (VLDL)��Ӷ��ڵ��Ѫ��HDLˮƽ��HDL��ɷ��淢��Ҫ��á��ˣ�CETP��Ƽ��Ϊ�ǶԹ�״��Ӳ��Ǳ��ҩ��֮һ��

��Ŀǰ��ڿ��CETP��Ƽ��Ҫ��֣�һ��Ĭɳ��anacetrapib��ɭ·͸Ԥ��С��ذ�ը��ǰ��ҩ��2016��֮ǰ��ϣ��󣻶��Ѿ��ٴ��evacetrapib��

��⣬Regeneron��˾/��ŵ�Ƶ�alirocumabҲ�ѽ��ٴ��Ƹߵ��̴�Ѫ֢��ѪҺ�еĵ��̴�ˮƽ��ߣ��ҩ�ڢ��ٴ��о��ʾ��ɫ��Ч��ɭ·͸Ԥ��ҩ��У��ȡ�á��ذ�ը��һ��ǰ��˾��Ƹߵ��̴�Ѫ֢��Ըߵ��̴�Ѫ֢��AMG 145��Ҳ�ѽ��ٴ��ADIS R&D Insight��˾Ԥ�⣬��PCSK9��Ƽ��2016��1�»��׼��ɭ·͸Ԥ�⣬��ҩ��۸߷�ʱ��۶�ɴ�40��Ԫ��

��ҩ���ý��ʽ�Ľ�

��1��ڶ��ڻ�û��ӡ��̵��²�Ʒ��Ŀǰ��ڿ��ͳ�Ч�ȵ��Ʒ��Ҫ��ŵ��ŵ�µ�Tresiba(degludec)��Ryzode(degludecplus)��Tresiba�ǳ��Ч�ȵ��ҩ���Ч��ʱ�䳬��24��Сʱ��侺��ƷΪ��ŵ�Ƶĳ�Ч�ȵ��ʱ(�ʾ��ȵ��)��Ч��ά��24Сʱ��Ryzodeg��һ�ֳ��Ч�ȵ��أ�Ҳ��Ƶ��ʱ�䣬��Ч�ȵ��Ŷ��ȵ��أ��ò�ʱʹ�á�

��Ͳ��ָ��Ҳ��Ͽ��Ч�ȵ��LY2605541��LY2963016��Ŀǰ��ʱ��1�ͺ�2��򲡵Ķ��о�(��ٴ��)��о��ʾ��LY2605541��ʱͬ��Ч�⣬��м��ʵ��洦��ܹ�ͨ��飬��ᳬԽ��֡�

��ȵ��ҩ�ǿ��ѡ��2��ת�� (SGLT2)��Ƽ�canagliflozinҲȡ��˻��ٴ��ݣ��һ��ٴ��ҩ��Ĭɳ��ġ��ذ�ը��2��ҩ��DPP-4��Ƽ�Januvia(sitagliptin��͡)��о��canagliflozin��м��洦��Ϥ��FDA��ص��ҩ��İ�ȫ�ԡ�ADIS R&D Insight��˾Ԥ�⣬canagliflozin��FDA��׼��2015��۶�ߴ�12��Ԫ��ʱ��ʩ��/��˹��SGLT2��Ƽ�dapagliflozin��FDAҪ��ṩ��İ�ȫ��ݶ��⵽�ӳ��׼��ŷ�ޣ��ҩ��2012��11�»��ŷ��ίԱ��׼��

��Դ�� ��й�ҽҩ��